SCHEMBL651709

SCHEMBL651709

Nc1ncc(/C=C2\SC(=Nc3ccc4cc[nH]c4c3)NC2=O)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
LMNA P02545 3/20 0.43
POLB P06746 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PSMD14 O00487 1/20 0.43
RAB9A P51151 4/20 0.42
MAPK1 P28482 2/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
ACHE P22303 4/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651710 1.00 MAPT (0.43) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649641 0.87 MAPT (0.43) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL10226222 0.87 MAPT (0.43) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649642 0.87 MAPT (0.43) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL652095 0.82 OGA (0.42) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL652094 0.82 OGA (0.42) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649940 0.81 NPC1 (0.61) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649939 0.81 NPC1 (0.61) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649013 0.80 PTPN7 (0.38) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL10226268 0.80 PTPN7 (0.38) MAPTKMT2AMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885KMT2A 3437/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.